Dr. Walter Orenstein Named to Board of Vaccine Think Tank
Sabin Vaccine Institute Convenes Sixth Annual Meeting at Walker’s Cay
NEW CANAAN, CT— Approximately forty of the world’s leading cancer vaccine researchers will meet this week at a scientific colloquium organized by the Albert B. Sabin Vaccine Institute. Convening in think-tank sessions, they will report on the latest developments in this promising field of therapy focused on stimulation of the body’s immune system to attack existing cancerous cells.
The U.S. Government's commitment to rapidly develop biomedical countermeasures against bioterrorist threats has stimulated a tremendous boost to biodefense research, a big push to expand research resources and facilities, and a growing dedication to build a robust biodefense industry.
Peter Hotez Presented Ashford Medal at 100th Anniversary Meeting of Medical Society
PHILADELPHIA, PA, December 3, 2003—Hartford, Connecticut native Peter J. Hotez, MD, PhD, FAAP claimed the 2003 Bailey K. Ashford Medal here today at the centenary meeting of the American Society of Tropical Medicine and Hygiene. Hotez is chairman of Microbiology and Tropical Medicine, The George Washington University, and senior fellow of the Albert Sabin Vaccine Institute, headquartered in New Canaan, Connecticut.
Sabin’s Ciro de Quadros Represents New Canaan Institute in Spain
GALICIA, SPAIN—The Sabin Vaccine Institute was represented at an international gathering in La Coluña, Spain to commemorate the 200th anniversary of the departure of the Balmis-Salvany Expedition.
Meeting In Bethesda, Maryland Focuses On Regulatory and Intellectual Property Issues
NEW CANAAN, CT, November 4, 2003—The Sabin Vaccine Institute, a non-profit research and education organization based in New Canaan, today concluded the second meeting of the Cancer Vaccine Consortium (CVC). The three-day meeting was held in Bethesda, Maryland and drew attendees from the United States, Canada and Europe. The purpose of the CVC is to enhance collaboration among companies undertaking research and development on cancer immunotherapies.